Scientists / Our Scientists

Andy Boswell

Distinguished Scientist Development, Translational PKPD ( joint appointment with Department of Translational Imaging), Development Sciences

Postdoc Mentor

"I am driven by the opportunity to apply a multidisciplinary approach to drug development in an effort to improve patients’ lives."

Years at Genentech

Publications at Genentech

Awards & Honors

Andy Boswell is currently a Distinguished Scientist and Postdoc Mentor in the Translational Pharmacokinetics and Pharmacodynamics (tPKPD) Department with a joint appointment in the Department of Translational Imaging (DTI) at Genentech. After completing a BS in Chemistry in his home state of Tennessee, Andy earned his PhD in Chemical Biology in 2004 at Washington University School of Medicine in Saint Louis, Missouri, where he specialized in synthesis and preclinical evaluation of radiotracers for nuclear medicine. He completed a postdoc, funded through a Cancer Research Training Award, on novel targeted molecular imaging agents at the NCI in Bethesda, Maryland.

Andy has more than 20 years of expertise in radiopharmaceutical chemistry including the incorporation of radioactive metals and halogens into antibodies and other biologically targeted molecules. During his tenure at Genentech, he has gained additional expertise in pharmacokinetics within tissue sites of action and in the application of labeling and non-invasive imaging techniques to drug development across various therapeutic areas.

Postdoctoral Mentor

My research vision is focused at the interface of chemistry and biology, with particular interest in using radiochemical probes to aid in the design, delivery and development of large molecule therapeutics. Our lab is uniquely poised to combine quantitative tissue-level radiometric drug measurements with cell-level fluorescence microscopic evaluation of receptor occupancy and tissue penetration. The ability to tackle scientific questions that arise in drug development presents a unique opportunity for a successful postdoctoral research project.

Featured Publication

On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy.

J Am Chem Soc. 2024

G. Li, M. Go, C. Ng, L. Bao, N. Agard, K. J. Chou, K. Kozak, T. Pillow, S. F. Yu, A. Boswell.

View Abstract

Since joining Genentech in 2007, I have been responsible for understanding the absorption, metabolism, distribution and excretion of many of our large molecule therapeutics to help ensure that we achieve adequate drug exposure in the appropriate tissue compartments. In the Investigative Pharmacokinetics group, we apply a multidisciplinary approach to characterize the biodistribution of antibodies, including radiochemical, biochemical and molecular imaging techniques.

Our group provides support across all therapeutic areas, including neuroscience and ophthalmology for which there are unique challenges in drug delivery and development. In my lab, we strive to provide guidance in designing and selecting the best molecule as well as the appropriate dose and regimen to achieve the pharmacologic exposure needed for efficacy.

Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling

EJNMMI Research, ISSN: 2191219X

Nicholas Cho; Jason Ho; Geoffrey del Rosario; Shang-Fan Yu; Gregory Z. Ferl; C. Andrew Boswell

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Andy Boswell

Distinguished Scientist Development, Translational PKPD ( joint appointment with Department of Translational Imaging), Development Sciences

Featured Publication

On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy.